Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Yantai New Drug Creation Shandong Laboratory have reported new degrader-antibody-drug conjugates (DACs) potentially useful for the treatment of cancer which are comprised of an antibody covalently bound to a molecular glue degrader moiety.